| XLS |
|
|
|
|
|
| ||
|
€ million |
Q2 2012 |
Q2 2011* |
Jan.–June |
Jan.–June | ||
| ||||||
|
Sales |
2,743.1 |
2,469.6 |
5,307.0 |
4,947.1 | ||
|
Royalty, license and commission income |
109.0 |
85.8 |
190.1 |
172.0 | ||
|
Total revenues |
2,852.1 |
2,555.4 |
5,497.1 |
5,119.1 | ||
|
|
|
|
|
| ||
|
Cost of sales |
–807.8 |
–759.8 |
–1,556.5 |
–1,398.8 | ||
|
Gross profit |
2,044.3 |
1,795.5 |
3,940.5 |
3,720.3 | ||
|
|
|
|
|
| ||
|
Marketing and selling expenses |
–617.3 |
–603.8 |
–1,203.8 |
–1,193.8 | ||
|
Royalty, license and commission expenses |
–151.7 |
–118.5 |
–271.7 |
–229.8 | ||
|
Administration expenses |
–142.6 |
–133.4 |
–279.0 |
–264.5 | ||
|
Other operating expenses and income |
–488.7 |
–278.2 |
–633.2 |
–215.3 | ||
|
Research and development |
–404.0 |
–368.4 |
–785.8 |
–747.2 | ||
|
Amortization of intangible assets |
–217.4 |
–319.0 |
–433.7 |
–567.2 | ||
|
Investment result |
0.5 |
2.0 |
0.5 |
2.1 | ||
|
Operating result (EBIT) |
23.2 |
–23.7 |
333.8 |
504.6 | ||
|
|
|
|
|
| ||
|
Financial result |
–69.7 |
–76.5 |
–135.8 |
–146.6 | ||
|
Profit before income tax |
–46.5 |
–100.1 |
198.0 |
358.0 | ||
|
|
|
|
|
| ||
|
Income tax |
–14.1 |
13.3 |
–83.4 |
–103.3 | ||
|
Profit after tax |
–60.5 |
–86.8 |
114.6 |
254.7 | ||
|
|
|
|
|
| ||
|
of which attributable to Merck KGaA shareholders |
–63.2 |
–88.7 |
109.5 |
249.7 | ||
|
of which non-controlling interest |
2.7 |
1.9 |
5.1 |
5.0 | ||
|
|
|
|
|
| ||
|
Earnings per share (in €) |
|
|
|
| ||
|
basic |
–0.29 |
–0.41 |
0.50 |
1.15 | ||
|
diluted |
–0.29 |
–0.41 |
0.50 |
1.15 | ||